Get the Stockscreener App
196.04
0.89%
1.72
After Hours:
196.00
-0.04
-0.02%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $196.04, with a volume of 1.51M.
It is up +0.89% in the last 24 hours and down -5.70% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$194.32
Open:
$196.28
24h Volume:
1.51M
Relative Volume:
1.18
Market Cap:
$28.44B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
18.90
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
+2.87%
1M Performance:
-5.70%
6M Performance:
-23.59%
1Y Performance:
-21.49%
1-Day Range:
$194.73
$199.99
1-Week Range:
$180.26
$199.99
52-Week Range:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
196.04 | 28.19B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
422.06 | 148.33B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
151.16 | 41.21B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.81 | 32.47B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.61 | 29.13B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
PBU The Pension Fund of Early Childhood & Youth Educators Makes New $7.93 Million Investment in ResMed Inc. $RMD - MarketBeat
Goldman Sachs Group Inc. Has $235.83 Million Stock Position in ResMed Inc. $RMD - MarketBeat
Cibc World Market Inc. Sells 8,768 Shares of ResMed Inc. $RMD - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Reduces Stock Position in ResMed Inc. $RMD - MarketBeat
Prudential PLC Raises Position in ResMed Inc. $RMD - MarketBeat
Can ResMed's Sleep Apnea Growth Justify Current Valuation Views? - Kalkine Media
CIBC Asset Management Inc Boosts Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
ResMed (RMD) Acquires Noctrix Health to Expand Sleep Disorder Portfolio - Insider Monkey
ResMed Inc. $RMD Shares Sold by Marietta Investment Partners LLC - MarketBeat
ResMed (ASX:RMD) Analysis: What’s Driving Investor Sentiment? - Kalkine
Ord Minnett Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
A Look at ResMed Inc (RMD) After 4.2% Gain -- GF Value $271.26 v - GuruFocus
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $320 - Moomoo
ResMed completes $340m Noctrix Health acquisition - Medical Device Network
Is ResMed a Better Buy Than Medtronic? - Trefis
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
ResMed, Inc. Hits 52-Week Low at USD 180.41 Amid Market Struggles - Markets Mojo
ResMed Inc. stock (US7611521078): RMD edges higher as institutional investors add exposure - AD HOC NEWS
ResMed (NYSE: RMD) counsel surrenders shares for RSU tax withholding - Stock Titan
Are CSL and ResMed shares buys at 52-week lows? - MSN
US: Resmed expands clinical sleep health portfolio with completion of Noctrix Health acquisition - Investors in Healthcare
Is It Time To Reassess ResMed (RMD) After A 25% Share Price Slide? - Yahoo Finance
Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million - Benzinga
Westpac Banking Corp Has $5.43 Million Position in ResMed Inc. $RMD - MarketBeat
Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million - Yahoo Finance
Resmed tackles restless legs syndrome with Noctrix Health takeover - Mugglehead Investment Magazine
Norges Bank Makes New Investment in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Acquired by Bank of New York Mellon Corp - MarketBeat
ResMed Inc. stock falls Friday, underperforms market - MSN
Could Cash Machine ResMed Stock Be Your Next Buy? - Trefis
Transcript : ResMed Inc. Presents at 46th Annual William Blair Growth Stock Conference, Jun-02-2026 04 - marketscreener.com
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Air Voel Strengthens CPAP Repair Support for ResMed PAP Device Users in Canada - Scott Coop
RMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Resmed completes $340M Noctrix takeover - MedTech Dive
Resmed completes Noctrix Health acquisition - Medical Buyer
ResMed Stock Delivers Strong Cash Yield – Upside Ahead? - Trefis
ResMed Inc. $RMD Shares Bought by BNP Paribas Financial Markets - MarketBeat
ResMed Completes Acquisition of Noctrix Health - Moomoo
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio - Koreabizwire
ResMed: Old fears return - intelligentinvestor.com.au
Resmed completes $340M acquisition of Noctrix Health - MassDevice
Resmed Closes Acquisition of Noctrix Health - Moomoo
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Wearable restless legs therapy offers drug-free sleep help for adults - Stock Titan
1 New 5-Star Stock This Week - Morningstar
ResMed: Transferring Coverage of Global Leader in Respiratory Care Devices - Morningstar
ResMed Inc. (RMD) Stock Analysis: Navigating a 42% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
RMD Technical Analysis | Trend, Signals & Chart Patterns | RESMED INC (NYSE:RMD) - ChartMill
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Resmed Inc Stock (RMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO |
May 07 '26 |
Option Exercise |
146.34 |
4,991 |
730,383 |
471,214 |
| Farrell Michael J. | Chairman and CEO |
May 07 '26 |
Sale |
207.82 |
4,991 |
1,037,233 |
466,223 |
2.44%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):